Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC

Cancer Discov. 2022 Jan;12(1):16-19. doi: 10.1158/2159-8290.CD-21-1429.

Abstract

HER3 is ubiquitously expressed in EGFR-mutant non-small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC.See related article by Jänne et al., p. 74.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Camptothecin / analogs & derivatives
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Protein Kinase Inhibitors
  • patritumab deruxtecan
  • EGFR protein, human
  • ErbB Receptors
  • Camptothecin